{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:55:00Z","timestamp":1794272100971,"version":"4.9.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ebiom.2022.104021","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T15:14:39Z","timestamp":1651245279000},"page":"104021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"special_numbering":"C","title":["Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5092-4306","authenticated-orcid":false,"given":"Johannes","family":"Levin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nand","family":"Sing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Melbourne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6857-4954","authenticated-orcid":false,"given":"Carla","family":"Mariner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Spillantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5082-9576","authenticated-orcid":false,"given":"Michal","family":"Wegrzynowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Dalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Ryazanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Leonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Griesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Weckbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Prager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Matthias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Giese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ebiom.2022.104021_bib0001","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ebiom.2022.104021_bib0002","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/mds.27431","article-title":"Movement disorder society criteria for clinically established early Parkinson's disease","volume":"33","author":"Berg","year":"2018","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104021_bib0003","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104021_bib0004","first-page":"61","article-title":"The differential diagnosis and treatment of atypical parkinsonism","volume":"113","author":"Levin","year":"2016","journal-title":"Dtsch Arztebl Int"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104021_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nm.4269","article-title":"alpha-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies","volume":"23","author":"Wong","year":"2017","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.ebiom.2022.104021_bib0006","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/mds.27894","article-title":"Multiple system atrophy: recent developments and future perspectives","volume":"34","author":"Meissner","year":"2019","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.ebiom.2022.104021_bib0007","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","article-title":"Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease","volume":"125","author":"Wagner","year":"2013","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104021_bib0008","doi-asserted-by":"crossref","first-page":"32","DOI":"10.15252\/emmm.201707825","article-title":"The diphenylpyrazole compound anle138b blocks Abeta channels and rescues disease phenotypes in a mouse model for amyloid pathology","volume":"10","author":"Martinez Hernandez","year":"2018","journal-title":"EMBO Mol Med"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104021_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamem.2019.183064","article-title":"Tau-induced mitochondrial membrane perturbation is dependent upon cardiolipin","volume":"1862","author":"Camilleri","year":"2020","journal-title":"Biochim Biophys Acta Biomembr"},{"issue":"8","key":"10.1016\/j.ebiom.2022.104021_bib0010","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1021\/acschemneuro.9b00320","article-title":"Cardiolipin promotes pore-forming activity of alpha-synuclein oligomers in mitochondrial membranes","volume":"10","author":"Ghio","year":"2019","journal-title":"ACS Chem Neurosci"},{"issue":"9","key":"10.1016\/j.ebiom.2022.104021_bib0011","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/j.bbagen.2015.05.021","article-title":"Anle138b and related compounds are aggregation specific fluorescence markers and reveal high affinity binding to alpha-synuclein aggregates","volume":"1850","author":"Deeg","year":"2015","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104021_bib0012","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.bbagen.2017.12.007","article-title":"Photophysics of diphenyl-pyrazole compounds in solutions and alpha-synuclein aggregates","volume":"1862","author":"Reiner","year":"2018","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104021_bib0013","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00401-015-1483-3","article-title":"Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies","volume":"130","author":"Wagner","year":"2015","journal-title":"Acta Neuropathol"},{"issue":"12","key":"10.1016\/j.ebiom.2022.104021_bib0014","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1021\/acschemneuro.7b00325","article-title":"Resolving the atomistic modes of Anle138b inhibitory action on peptide oligomer formation","volume":"8","author":"Matthes","year":"2017","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104021_bib0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13195-019-0522-z","article-title":"Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tau","volume":"11","author":"Brendel","year":"2019","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104021_bib0016","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00401-014-1265-3","article-title":"The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset","volume":"127","author":"Levin","year":"2014","journal-title":"Acta Neuropathol"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104021_bib0017","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/mds.27562","article-title":"Anle138b modulates alpha-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy","volume":"34","author":"Heras-Garvin","year":"2019","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104021_bib0018","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00401-019-02023-x","article-title":"Depopulation of dense alpha-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model","volume":"138","author":"Wegrzynowicz","year":"2019","journal-title":"Acta Neuropathol"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104021_bib0019","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3233\/JPD-202128","article-title":"Parkinson's disease drug therapies in the clinical trial pipeline: 2020","volume":"10","author":"McFarthing","year":"2020","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104021_bib0020","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s13311-019-00714-7","article-title":"Nucleic acid-based therapeutics for Parkinson's disease","volume":"16","author":"Nakamori","year":"2019","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ebiom.2022.104021_bib0021","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3389\/fnins.2020.00498","article-title":"\u201cLRRK2: autophagy and lysosomal activity\u201d","volume":"14","author":"Madureira","year":"2020","journal-title":"Front Neurosci"},{"issue":"514","key":"10.1016\/j.ebiom.2022.104021_bib0022","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau6870","article-title":"A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease","volume":"11","author":"Burbulla","year":"2019","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104021_bib0023","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.3233\/JAD-170601","article-title":"The relevance of iron in the pathogenesis of multiple system atrophy: a viewpoint","volume":"61","author":"Kaindlstorfer","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.ebiom.2022.104021_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101339","article-title":"Effects of monoclonal antibodies against amyloid-beta on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease","volume":"68","author":"Avgerinos","year":"2021","journal-title":"Ageing Res Rev"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104021_bib0025","doi-asserted-by":"crossref","first-page":"16165","DOI":"10.1038\/s41598-018-34490-9","article-title":"The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease","volume":"8","author":"Price","year":"2018","journal-title":"Sci Rep"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422002055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422002055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:14:43Z","timestamp":1762456483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396422002055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":25,"alternative-id":["S2352396422002055"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104021","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104021"}}